14.94
-0.15 (-0.99%)
Market Trend
Short Term | Medium Term | ||
Industry | Medical Instruments & Supplies (US) | Mixed | Bearish |
Medical Instruments & Supplies (Global) | Mixed | Mixed | |
Stock | Bausch + Lomb Corporation | Bullish | Bearish |
Stockmoo Score
Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
|
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
Investment Style | Mid Core |
Ownership
Name | Date | Shares Held |
---|---|---|
Freshford Capital Management, Llc | 31 Mar 2024 | 1,165,280 |
Point72 Europe (London) Llp | 31 Mar 2024 | 506,909 |
52 Weeks Range | ||
Price Target Range | ||
High | 20.00 (RBC Capital, 33.87%) | Buy |
Median | 18.50 (23.83%) | |
Low | 15.50 (Evercore ISI Group, 3.75%) | Hold |
Average | 18.13 (21.35%) | |
Total | 2 Buy, 2 Hold | |
Avg. Price @ Call | 15.96 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Deutsche Bank | 01 Aug 2024 | 18.00 (20.48%) | Hold | 16.86 |
RBC Capital | 01 Aug 2024 | 20.00 (33.87%) | Buy | 16.86 |
Raymond James | 10 Jul 2024 | 19.00 (27.18%) | Buy | 15.47 |
Evercore ISI Group | 02 Jul 2024 | 15.50 (3.75%) | Hold | 14.66 |
No data within this time range.
Date | Type | Details |
---|---|---|
31 Jul 2024 | Announcement | Bausch + Lomb Announces Second-Quarter 2024 Results |
11 Jul 2024 | Announcement | Bausch + Lomb Will Release Second-Quarter 2024 Financial Results on July 31 |
08 Jul 2024 | Announcement | Millions of Americans Experience Dry Eye Symptoms, Yet New National Survey Shows Sufferers Struggle to Find Relief |
17 Jun 2024 | Announcement | Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |